PDF《OUR MISSION:》

Annual Report OUR MISSION : FOR EVERYONE'

S HEALTH 我们的使命 为每个人的健康 2018年度报告 Corporate Structure Financial Summary Corporate Profile History of Development Chairman'

s Statement Highlights of the Year Management Discussion and Analysis Profiles of Directors, Supervisors and Senior Management Report of the Board of Directors Report of the Board of Supervisors Corporate Governance Report Independent Auditor'

s Report Consolidated Statement of Profit or Loss and other Comprehensive Income Consolidated Statement of Financial Position Consolidated Statement of Changes in Equity Consolidated Cash Flow Statement Notes to the Financial Statements Definitions Corporate Information 企业架构 财务摘要 公司简介 发展历程 董事长报告书 年度大事记 管理层讨论及分析 董事、监事及高级管理人员简介 董事会报告 监事会报告 企业管治报告 独立核数师报告 综合损益及其他全面收益表 综合财务状况表 综合权益变动表 综合现金流量表 财务报表附注 释义 公司资料

2 3

4 6

7 9

10 33

45 77

81 108

119 120

122 123

124 222

226 Contents 目录 YICHANG HEC CHANGJIANG PHARMACEUTICAL CO.

, LTD. 宜昌东阳光长江药业股份有限公司

2 CORPORATE STRUCTURE 企业架构 Shenzhen HEC Industrial Development Co., Ltd 深圳市东阳光实业发展有限公司 Guangdong HEC Technology Holding Co., Ltd. 广东东阳光科技控股股份 有限公司 Ruyuan Yangzhiguang Aluminium Development Co., Ltd. 乳源阳之光铝业发展 有限公司 Holders of A Shares A股股东 HEC Pharm Co., Ltd. 宜昌东阳光药业股份有限公司 Linzhi HEC Pharmaceutical Investment Co., Ltd. 林芝东阳光药业投资有限公司 YiChang HEC Chang Jiang Pharmaceutical Co., Ltd. 宜昌东阳光长江药业股份有限公司 Yichang HEC Pharmaceutical Co., Ltd. 宜昌东阳光医药有限公司 Yichang HEC Pharmaceutical Manufacturing Co., Ltd. 宜昌东阳光制药有限公司 Dongguan Yangzhikang Pharmaceutical Co., Ltd. 东莞市阳之康医药 有限责任公司 Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. 东莞东阳光太景医药研发 有限责任公司 Holders of H Shares H 股股东 Ruyuan Yao Autonomous County HEC Corporate Management Co., Ltd. 乳源瑶族自治县东阳光企业 管理有限公司 0.40% 100.00% 100.00% 60.70% Dongguan HEC Industrial Development Co., Ltd. 东莞市东阳光实业发展有限公司 6.50% 100.00% 27.97% 46.68% 4.25% 50.04% 100.00% 100.00% 100.00% 60.00% 49.96% 3.02% 18.08% ANNUAL REPORT

2018 年报

3 FINANCIAL SUMMARY 财务摘要 Set out below is the financial summary for the year ended

31 December

2018 ( the year or the reporting period ): Revenue of the Group in

2018 increased by 56.75% to RMB2,510.48 million as compared with 2017. Profit and total comprehensive income attributable to the equity shareholders of the Company in

2018 increased by 45.66% to RMB942.54 million as compared with 2017. Basic/diluted earnings per share in

2018 increased by 46.15% to RMB2.09 as compared with 2017. The Board of Directors proposed to pay a final cash dividend of RMB0.6 per share, subject to the approval by the shareholders at the forthcoming AGM to be held by the Company.

2014 2015

2016 2017

2018 二零一四年 二零一五年 二零一六年 二零一七年 二零一八年 RMB'

000 RMB'

000 RMB'

000 RMB'

000 RMB'

000 人民币千元 人民币千元 人民币千元 人民币千元 人民币千元 Operating result 经营业绩 Revenue 营业额 440,904 692,910 941,504 1,601,567 2,510,476 Gross profit 毛利 321,075 514,576 727,270 1,321,151 2,111,667 Profit from operation 经营溢利 205,445 339,605 460,299 752,484 1,103,742 Profit before taxation 除税前溢利 163,115 314,706 453,066 748,195 1,102,324 Profit and total comprehensive income attributable to equity shareholders of the Company 本公司权益股东 应占溢利及全面收益总额 135,343 265,750 380,597 647,101 942,536 Profit margin 利润率 Gross profit margin 毛利率 72.82% 74.26% 77.25% 82.49% 84.11% Net profit margin 纯利率 30.70% 38.35% 40.42% 39.11% 35.90% Earnings per share 每股盈利 Basic &